Frontotemporal DementiaEFRONTNCT05075187
Epidemiological Study in FRONtoTemporal Dementia
An observational study of Frontotemporal Dementia, run by CENTOGENE GmbH Rostock at 37 sites in 7 countries.
Trial summary
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD. Read more about this study
- Who is it for?
- Ages 25 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Frontotemporal Dementia
- What is being tested?
- Genetic Screening
- How many people
- 2,287 participants
- Where
- 37 sitesin 7 countries
- Study dates
- 1 Sep 2021to 9 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants diagnosed with Frontotemporal Dementia (FTD) and participants clinically suspected for FTD
Who may be able to join
- Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian
- The participant is aged between 25 to 85 years
- The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD
Who cannot join
None listed.
Trial locations and contacts
37 sites in 7 countries.
37 sites in 7 countries
Germany11 sites
RWTH Aachen University
Aachen, 52074
Hochtaunus-Kliniken gGmbH
Bad Homburg, 61352
AGZ of Charite Universitätsmedizin Berlin
Berlin, 12200
University Hospital Cologne
Cologne, 50937
University Hospital Dresden
Dresden, Saxony, 01307
University Medical Center Hamburg Eppendorf
Hamburg, Schleswig-Holstein, 20246
Asklepios Klinik Nord - Ochsenzoll
Hamburg, 22419
Hanau Hospital
Hanau, Hesse, 63450
Gertrudis Klinik
Leun, Hesse, 35638
University of Lübeck
Lübeck, Schleswig-Holstein, 23562
University Hospital Rostock
Rostock, 18057
Portugal6 sites
Hospital Garcia de Orta
Almada, 2805-267
Unidade Psiquiatrica Privada de Coimbra
Coimbra, 3000-606
Hospital da Senhora da Oliveira Guimaraes
Guimarães, 4835-044
Hospital Beatriz Ângelo
Loures, 2674-514
Hospital Pedro Hispano
Matosinhos Municipality, 4464-513
CNS - campus neurológico Torres Vedras
Torres Vedras, 2560-280
Spain6 sites
Hospital Universitari vall D´hebron
Barcelona, 08035
Universitary Hospital La Princesa
Madrid, 28006
Hospital Clinico San Carlos
Madrid, 28040
Hospital Universitario 12 de Octubre
Madrid, 28041
Clinica Universidad de Navarra
Pamplona, 31008
Marqués de Valdecilla University Hospital
Santander, 39011
Turkey (Türkiye)6 sites
Baskent University
Ankara, 06100
Hacettepe University
Ankara, 06100
Koç University Hospital
Istanbul, 34010
Istanbul University
Istanbul, 34080
Bezmialem Vakif University
Istanbul, 34093
Izmir Economy University Medikalpark Hospital
Izmir, 35575
Italy4 sites
Università degli studi Gabriele D'Annunzio Chieti-Pescara
Chieti, 66100
Azienda Ospedaliera Universitaria Federico II di Napoli
Naples, 80131
Azienda Ospedaliero-Universitaria di Parma
Parma, 43126
Azienda USL-IRCCS of Reggio Emilia
Reggio Emilia, 42121
Greece2 sites
Mediterraneo Hospital
Athens, 16675
University of Ioannina
Ioannina, 45110
About this study
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.
Read the detailed description
Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.
- Conditions
- Frontotemporal Dementia
- Being tested
- Genetic Screening
- Medical subject headings
- Frontotemporal Dementia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Genetic ScreeningDiagnostic test
Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.
| Study group | Role | What they receive |
|---|---|---|
| Participants diagnosed with Frontotemporal Dementia | Participants diagnosed with Frontotemporal Dementia Receives: Diagnostic Test: Genetic Screening |
What is being measured
The primary outcome is the main question the study is designed to answer.
To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants
Measured: 15 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Oct 2021
- Study start1 Sep 2021
- Primary completion9 Jan 2024
- Study completion9 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Frontotemporal DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 2,287 participants (actual)
Sponsor and investigators
- Lead sponsor
- CENTOGENE GmbH Rostock
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Peter Bauer, Ph.D, Principal investigator, Centogene GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05075187
- Sponsor's protocol ID
- EFRONT 05-2021
- Acronym
- EFRONT
- Status last verified
- Apr 2026
- First submitted
- 30 Sep 2021
- Last updated
- 9 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epidemiological Study in FRONtoTemporal Dementia
- ClinicalTrials.gov ID
- NCT05075187
- Acronym / sponsor ID
- EFRONT / EFRONT 05-2021
- Conditions
- Frontotemporal Dementia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,287 participants (actual)
- Lead sponsor
- CENTOGENE GmbH RostockIndustry (pharma, biotech, devices)
- Study start
- 1 Sep 2021 (actual)
- Primary completion
- 9 Jan 2024 (actual)
- Study completion
- 9 Jan 2024 (actual)
- First posted
- 12 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.
Detailed description
Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants diagnosed with Frontotemporal Dementia | – | Diagnostic Test: Genetic ScreeningParticipants diagnosed with Frontotemporal Dementia |
Who may qualify
- Ages
- 25 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants diagnosed with Frontotemporal Dementia (FTD) and participants clinically suspected for FTD
Key inclusion criteria (3 listed)
- Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian
- The participant is aged between 25 to 85 years
- The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Genetic ScreeningBlood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD. | Diagnostic test | Participants diagnosed with Frontotemporal Dementia |
Primary outcome
To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants
Time frame: 15 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2026.
Related trials for Frontotemporal Dementia
RecruitingObservational study
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
RecruitingObservational study
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
Niemann-Pick Disease, Type C
RecruitingObservational study
Speech and Language Interventions for Italian People With PPA
Primary Progressive Aphasia(PPA)
Enrolling by invitationPhase 2
Alzheimer's Tau Platform: Regimen A - AADvac1
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Active, not recruitingPhase 2
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
GM2 Gangliosidosis, Niemann-Pick Type C Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Bauer, Ph.D principal investigator
Centogene GmbH
37 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Frontotemporal Dementia, run by CENTOGENE GmbH Rostock at 37 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 37 sites in Germany, Portugal, Spain, Turkey (Türkiye), Italy and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants (time frame: 15 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026.